Core Viewpoint - The report from Citi indicates that WuXi AppTec is expected to see a 9% revenue growth in Q4 2025 and a 36% increase in adjusted net profit, surpassing market expectations by 2% and 3% respectively, driven by its strong integrated CRDMO model and robust growth in the WuXi TIDES business, along with China's competitive advantage in the global small molecule supply chain [1] Group 1 - The strong performance of WuXi AppTec is attributed to its comprehensive CRDMO model and the significant growth of its WuXi TIDES business [1] - The company is expected to outperform the market, with adjusted net profit growth projected to be in the high double digits (approximately 16% to 19%) for 2026, exceeding the market expectation of 15% [1] - Citi maintains its forecasts for 2025 to 2027 and has set a target price of HKD 143.4 for WuXi AppTec, rating it as "outperform" in the Chinese CRO/CDMO sector [1]

Core Viewpoint - The report from Citi highlights that WuXi AppTec (603259)(02359) is expected to see a 9% revenue growth in Q4 2025 and a 36% increase in adjusted net profit, surpassing market expectations by 2% and 3% respectively, driven by its strong integrated CRDMO model and robust growth in the WuXi TIDES business, along with China's competitive advantage in the global small molecule supply chain [1] Group 1 - WuXi AppTec is identified as the preferred stock in the Chinese CRO/CDMO sector with a target price of HKD 143.4 and an "outperform" rating [1] - The outlook for 2026 suggests that profitability will be more important than valuation expansion for the Chinese healthcare industry, with WuXi AppTec expected to outperform the market [1] - The firm maintains its profit forecasts for 2025 to 2027, anticipating a high double-digit growth (approximately 16% to 19%) in adjusted net profit for WuXi AppTec in 2026, exceeding the market expectation of 15% [1]

Core Viewpoint - The report from Credit Lyonnais indicates that WuXi AppTec (02359) is expected to achieve a 9% revenue growth and a 36% increase in adjusted net profit for Q4 2025, surpassing market expectations by 2% and 3% respectively, driven by its strong CRDMO model and robust growth in WuXi TIDES business [1] Group 1: Financial Performance - WuXi AppTec's revenue for Q4 2025 is projected to grow by 9% [1] - Adjusted net profit for the same period is expected to increase by 36%, exceeding market expectations [1] - The company is anticipated to maintain a high double-digit growth in adjusted net profit for 2026, estimated between 16% to 19%, which is above the market expectation of 15% [1] Group 2: Market Position and Outlook - Credit Lyonnais has designated WuXi AppTec as the preferred stock in the Chinese CRO/CDMO sector, with a target price of HKD 143.4 and an "outperform" rating [1] - The report suggests that profitability will be more important than valuation expansion for the Chinese healthcare industry in 2026, with WuXi AppTec expected to outperform the market [1]